Pfizer Relpax
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eletriptan will "probably" see approval by the end of the year, Pfizer predicts in a July 26 investor conference call. FDA issued an "approvable" letter for the anti-migraine agent Oct. 29, 1999. The company's response to the approvable letter is receiving a six-month revie